Roth Capital Previews bluebird bio (BLUE) Ahead of EHA Abstract

Roth Capital analyst Debjit Chattopadhyay reiterated a Buy rating and $145 price target on Bluebird Bio (NASDAQ: BLUE) ahead of the EHA abstract on May 21st.

According to Chattopadhyay, the abstract "could highlight early outcomes from the single SCD patient and insights into beta-thalassemia."

"We are optimistic about the success in SCD (despite being a multi-organ disease), but note that clinical resolution could take longer," the analyst said. "If bluebird files for accelerated approval (beta-thalassemia) based on 100% cure rates, no clonal amplification, and BT-designation, there could be significant upside to our target."

For an analyst ratings summary and ratings history on Bluebird Bio click here. For more ratings news on Bluebird Bio click here.

Shares of Bluebird Bio closed at $154.42 yesterday.

You May Also Be Interested In

• UBS Upgrades FuelCell Energy (FCEL) to Buy, 'we would be buyers ahead of any capacity expansion announcement'
• Hut 8 Mining Corp. (HUT) PT Raised to $165 at Benchmark as Numbers Move Quickly
• Stephens Downgrades WW Grainger (GWW) to Equal Weight